During the corresponding time, Pluri Inc saw a revenue deteriorated by -15.83 % year on year, sequentially revenue grew by 100.6 %. While revenue at the Pluri Inc 's corporate clients
Pluri Inc's Comment on Sales, Marketing and Customers
The company operates in global markets for aesthetics, wellness, and longevity products, with significant presence in North America, Europe, and Asia. Its customers include multinational consumer-products, pharmaceutical, biotechnology, and medical-aesthetics companies, as well as specialized skincare, wellness, and direct-to-consumer brands based in the United States, Europe, and Asia. In January 2024, the company launched its PluriCDMO™ division, which provides cell therapy development and manufacturing services to pharmaceutical and biotechnology companies, supporting projects from early preclinical development through late-stage clinical trials and commercialization. PluriCDMO™ has established multiple commercial agreements and serves clients in regulated life sciences environments, including those manufacturing medical devices. Notable customers and partners mentioned in company filings include Bar-Ilan University, Bar-Ilan University Research and Development Company Ltd., Berlin-Brandenburg Center for Regenerative Therapies at Charité – University Medicine Berlin, BIRAD, BIRAD–Research & Development Company Ltd., Bühler, Bühler Group, CHA, Charité – University Medicine Berlin, European Investment Bank, Ever After Foods, Fukushima Medical University, Hemafund, TES Holdings Co., Ltd., and the U.S. Department of Defense.
Pluri, a leading player in the agriculture and food production industry, has recently unveiled a groundbreaking initiative aimed at enhancing the global supply of sustainable vegetables. The company has inked a $1 million proof of concept agreement with a vision to develop innovative production methods, shorten supply chains, and promote the advancement of sustainable agriculture worldwide.The collaboration s primary is to address the pressing challenges facing the vegetable supply chain, such as limited availability of fresh produce, long distribution routes, and unsustainable farming practices. Pluri aims to reengineer conventional agricultural models by leveraging cutting-edge technologies and novel prod...
U.S. National Institutes of Health Continues Funding for Pluri Inc. s PLX-R18 Acute Radiation Syndrome ContractHAIFA, Israel, June 06, 2024 - Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a leading biotechnology company specializing in transforming cells into solutions, has recently announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will be providing an additional $1.4 million in funding to support the second year of a three-year contract. The contract, initially signed in July 2023, has a total value of $4.2 million aimed at manufacturing the PLX-R18 cell therapy and conducting studies for its potential use in treating hematopo...
Pluri Inc., a renowned biotechnology powerhouse, globally esteemed for transforming cells into viable treatment solutions, aspires to revolutionize the cancer treatment sector once again. On May 02, 2024, the company unveiled its paradigm-altering platform based on Mucosal Associated Invariant T (MAIT) cells, exclusively dedicated to immunotherapy treatment for solid tumors.As per the National Cancer Institute, solid tumors include different types of cancer like breast, colon, lung, and prostate cancers - comprises a substantial number of approximately 1.9 million annual cases in the U.S. alone. To deliver solutions for this extensive patient population, Pluri Inc. is chartering previously unexplored territo...
In a groundbreaking development for the treatment of Idiopathic Pulmonary Fibrosis (IPF), cell therapy pioneer Remedy Cell has teamed up with PluriCDMO to manufacture their highly anticipated product candidate, RC-0315. This partnership aims to revolutionize IPF treatment by harnessing the potential of cell-derived cell-free drugs. As a Contract Development and Manufacturing Organization (CDMO), Pluri will play a crucial role in supporting Remedy Cell s manufacturing and production process for this novel therapeutic approach. In a recent collaboration, PluriCDMO a leading CDMO firm renowned for its expertise in cell therapies has been chosen by Remedy Cell to support the manufacture of their promising pr...
Pluri Inc’s Comment on Sales, Marketing and Customers
The company operates in global markets for aesthetics, wellness, and longevity products, with significant presence in North America, Europe, and Asia. Its customers include multinational consumer-products, pharmaceutical, biotechnology, and medical-aesthetics companies, as well as specialized skincare, wellness, and direct-to-consumer brands based in the United States, Europe, and Asia. In January 2024, the company launched its PluriCDMO™ division, which provides cell therapy development and manufacturing services to pharmaceutical and biotechnology companies, supporting projects from early preclinical development through late-stage clinical trials and commercialization. PluriCDMO™ has established multiple commercial agreements and serves clients in regulated life sciences environments, including those manufacturing medical devices. Notable customers and partners mentioned in company filings include Bar-Ilan University, Bar-Ilan University Research and Development Company Ltd., Berlin-Brandenburg Center for Regenerative Therapies at Charité – University Medicine Berlin, BIRAD, BIRAD–Research & Development Company Ltd., Bühler, Bühler Group, CHA, Charité – University Medicine Berlin, European Investment Bank, Ever After Foods, Fukushima Medical University, Hemafund, TES Holdings Co., Ltd., and the U.S. Department of Defense.
Sources:
Pluri Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pluri Inc’s corporate clients.
For your research, we’ve provided 9 tables on Pluri Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
